You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 127 No. 11, November 1992 TABLE OF CONTENTS
  Archives
  •  Online Features
  PAPERS PRESENTED AT THE 45TH ANNUAL CANCER SYMPOSIUM OF THE SOCIETY OF SURGICAL ONCOLOGY, NEW YORK, NY, MARCH 15-18, 1992
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

99mTc—IMMU-4 Monoclonal Antibody Scan in Colorectal Cancer

A Prospective Study

Miguel A. Rodriguez-Bigas, MD; Suraj Bakshi, MD; Paul Stomper, MD; Leslie E. Blumenson, PhD; Nicholas J. Petrelli, MD

Arch Surg. 1992;127(11):1321-1324.


Abstract

• A blinded prospective study of 34 patients with colorectal adenocarcinoma using the FabI fragment of the anticarcinoembryonic antigen monoclonal antibody type IMMU-4 labeled with technetium 99m was conducted to compare, on a lesion-by-lesion basis, the findings of radioimmunoscintigraphy, preoperative computed tomography, and exploratory celiotomy. Of 115 lesions detected at surgery, 113 were adenocarcinoma. Radioimmunoscintigraphy detected 59 lesions and computed tomography detected 62; both studies combined detected 72. Twenty-nine (54%) lesions missed by radioimmunoscintigraphy and 24 (45%) missed by computed tomography were 1 cm or smaller. When both studies were combined, the sensitivities were 90%, 24%, and 42%, and the specificities were 52%, 86%, and 61% for hepatic, extrahepatic intra-abdominal, and pelvic lesions, respectively. In 10 patients, additional information obtained with the radioimmunoscintigram could have altered the treatment of these patients. In this study, radioimmunodetection scan was complementary to computed tomographic scan in the examination of patients with colorectal carcinoma.

(Arch Surg. 1992;127:1321-1324)



Author Affiliations

From the Departments of Surgical Oncology and Endoscopy (Drs Rodriguez-Bigas and Petrelli), Nuclear Medicine (Dr Bakshi), Diagnostic Radiology (Dr Stomper), and Biomathematics (Dr Blumenson), Roswell Park Cancer Institute, Buffalo, NY.


Footnotes

Accepted for publication July 25, 1992.

Presented at the 45th Annual Cancer Symposium of the Society of Surgical Oncology, New York, NY, March 17, 1992.

Reprint requests to Department of Surgical Oncology and Endoscopy, Roswell Park Cancer Institute, Elm and Carlton streets, Buffalo, NY 14263 (Dr Petrelli).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

FDG PET and Immunoscintigraphy with 99mTc-Labeled Antibody Fragments for Detection of the Recurrence of Colorectal Carcinoma
Willkomm et al.
JNM 2000;41:1657-1663.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1992 American Medical Association. All Rights Reserved.